 |
Letzte Umfrage
|
|
Welches Angebot von migraeneinformation.de schätzen Sie besonders?
|
| Forum | |  | 84,9% | | News | | | 83,6% | | Umfragen | | | 27,4% | | Termine | | | 19,2% | | Links | | | 11,0% | | Infos zu Medikam. | | | 26,0% | | Infos zu Ernährung | | | 71,2% | | Infos zu Therapien | | | 27,4% | | Online-Tests | | | 43,8% | | Migräne-Kalender | | | 20,5% | |
|
|
Cinnarizin erfolgreich in der Migräneprophylaxe [Pharma]
01 Mai 06
 |
Signifikante Erfolge in einer Open-Label-Studie |
Cinnarizin ist ein Mittel zur Verbesserung der zerebralen Durchblutung und wird unter anderem bei Seekrankheit eingesetzt. Gelegentlich wurde berichtet, dass auch Migräneauren damit abgekürzt werden können (Akutbehandlung).
Die vorliegende Studie hat nun untersucht, inwieweit Cinnarizin in der Migräneprophylaxe eingesetzt werden kann.
Die Ergebnisse:
Nach 2-wöchentlicher Behandlung reduzierte sich die Migränefrequenz durchschnittlich um 35 Prozent, nach 6 bzw. 10 Wochen um 74 Prozent und nach 14 Wochen um 75 Prozent.
Die Schwere und Dauer der einzelnen Attacken verringerten sich ebenfalls signifikant.
Abstract:
Open-label trial of cinnarizine in migraine prophylaxis.
OBJECTIVE: To assess the effectiveness and safety of cinnarizine as a migraine-preventive therapy. METHODS: Sixty patients with more than 2 migraine headache attacks during a 4-week baseline entered the study and received a 25-mg tablet cinnarizine twice daily for the first 3 days and then 3 times daily. They were assessed on weeks 2, 6, 10, and 14. Reduction from baseline in 4-week migraine headache rate was the primary efficacy variable. Reduction in migraine attacks duration and severity was also evaluated. RESULTS: The mean reduction in 4-week migraine headache rate was 4.6 +/- 2.2 from the baseline of 6.2 +/- 2.2 after 14 weeks of treatment, which was statistically significant (P < 0.001). Percent reduction in 4-week migraine frequency was 35% after 2 weeks, 74% after 6 weeks, 74% after 10 weeks, and 75% after 14 weeks of treatment. Significant reduction in attack duration (P < 0.001) and severity (P < 0.001) was also noted. No serious adverse events were observed in this series of patient. CONCLUSION: Cinnarizine is an efficacious and well-tolerated prophylactic antimigraine medication, which has early onset effectiveness.
Togha M, Ashrafian H, Tajik P. Open-label trial of cinnarizine in migraine prophylaxis. Headache. 2006 Mar;46(3):498-502.
|
Kommentare (0)
©migraeneinformation.de 2004 - 2019
|
|
|
|
|
Donnerstag, 18. Juli 2019 |
|
|
|
 Das Wetter für
Frankfurt am Main |
|
|
| Migräne-Blog |
| Juli 2019 |
| Mo |
Di |
Mi |
Do |
Fr |
Sa |
So |
KW |
| 01 |
02 |
03 |
04 |
05 |
06 |
07 |
27. |
| 08 |
09 |
10 |
11 |
12 |
13 |
14 |
28. |
| 15 |
16 |
17 |
18 |
19 |
20 |
21 |
29. |
| 22 |
23 |
24 |
25 |
26 |
27 |
28 |
30. |
| 29 |
30 |
31 |
|
|
|
|
31. |
| Juni |
|
|
|
|
|
